查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1618780

癌症藥物市場：按適應症、藥物類別、給藥途徑、分銷和最終用途 - 2025-2030 年全球預測

Oncology Drugs Market by Indication (Bladder Cancer, Breast Cancer, Cervical Cancer), Drug Class (Chemotherapy, Hormonal Therapy, Immunotherapy), Route of Administration, Distribution, End-use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年癌症治療市值為1757.8億美元，預計到2024年將達到1884.1億美元，複合年成長率為7.64%，到2030年將達到2944.2億美元。

癌症治療市場是根據不同癌症的治療範圍來定義的，包括化療、免疫療法、標靶治療和荷爾蒙療法等多種治療方法。全球癌症發生率的上升凸顯了對癌症藥物的需求，推動了對改善患者生存和生活品質的創新治療的需求。這些藥物具有廣泛的用途，包括醫院、癌症研究中心和專科診所，最終用途為兒科、成人和老年患者。影響該市場的主要成長要素包括生物技術的進步、癌症研究資金的增加以及新療法的不斷增加。此外，隨著世界各地監管機構強調藥物核准速度，個人化醫療和生物相似藥的開發潛力帶來了利潤豐厚的機會。為了利用這些機會，企業應專注於投資研發，促進與研究機構的合作，並開拓醫療需求未被滿足的新興市場。然而，市場成長面臨的挑戰包括治療成本上升、嚴格的法律規範以及治療方法的潛在副作用，這些可能會阻礙患者的取得和負擔能力。此外，因地區而異的複雜報銷情況也導致了進一步的延誤。創新應優先考慮精準腫瘤學，即根據基因圖譜客製化治療方法，並探索整合不同治療方法以獲得卓越療效的聯合治療。總體而言，市場動態是一個動態市場，其特徵是技術快速發展和高度競爭。公司必須保持敏捷，不斷適應科學進步和政策變化，以保持競爭力。對人工智慧和機器學習等數位健康技術的策略性投資可以進一步改善藥物開發流程和患者治療結果，最終推動這個強勁行業的業務成長。

主要市場統計
基準年[2023] 1757.8億美元
預計年份 [2024] 1884.1億美元
預測年份 [2030] 2944.2億美元
複合年成長率（%） 7.64%

市場動態：揭示快速發展的癌症藥物市場的關鍵市場洞察

供需的動態交互作用正在改變癌症藥物市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 全球癌症盛行率迅速上升
    • 增加抗癌藥物開發的投資和政府資助
    • 擴大個人化醫療的研究與開發
  • 市場限制因素
    • 精準醫學治療相關的高成本
  • 市場機會
    • 基因組定序技術和生物技術的進展
    • 利用生物標記進行藥物開發的進展
  • 市場挑戰
    • 嚴格的監管要求和藥物開發的複雜性

波特五力：駕馭癌症藥物市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對癌症藥物市場的影響

外部宏觀環境因素在塑造癌症治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解癌症治療藥物市場的競爭狀況

對癌症治療藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣癌症治療市場供應商的績效評估

FPNV定位矩陣是評估癌症治療市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議 繪製癌症治療市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，癌症藥物市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球癌症發生率正在迅速增加
      • 增加對癌症藥物開發的投資和政府資助
      • 擴大個人化醫療的研究與開發
    • 抑制因素
      • 精準醫學治療相關的高成本
    • 機會
      • 基因組序列分析技術和生物技術的進展
      • 生物標記主導的藥物開發
    • 任務
      • 嚴格的監管要求和藥物開發的複雜性
  • 市場區隔分析
    • 藥物類別：由於準確性和副作用較少，標靶治療變得越來越重要
    • 最終用途：癌症診所的持續擴張加速了癌症藥物的需求
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依適應症分類的癌症治療藥物市場

  • 膀胱癌
  • 乳癌
  • 子宮頸癌
  • 大腸直腸癌
  • 食道癌
  • 腎癌
  • 肝癌
  • 肺癌
  • 攝護腺癌
  • 胃癌

第7章按藥物類別分類的癌症藥物市場

  • 化療
  • 荷爾蒙療法
  • 免疫療法
  • 標靶治療

第8章癌症藥物市場：依給藥途徑分類

  • 靜脈
  • 口服
  • 話題

第9章 癌症治療藥物市場經銷商

  • 線下藥局
    • 醫院藥房
    • 零售藥房
  • 網路藥房

第10章癌症藥物市場：依最終用途分類

  • 家庭保健
  • 醫院
  • 癌症專科診所

第11章：美洲的癌症藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章 亞太地區抗癌藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲的癌症藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • FDA核准XTANDI 用於高風險前列腺癌治療
    • 武田製藥的 FRUZAQLA 獲得 FDA核准用於治療轉移性大腸癌
    • FDA核准武田的 FRUZAQLA，一種治療轉移性大腸直腸癌的新療法
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • Agenus Inc.
  • Amgen Inc.
  • Aspen Pharmacare Holdings Limited
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BeiGene, Inc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Debiopharm International SA
  • Eli Lilly and Company
  • EMD Serono, Inc. by Merck KGaA
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Pfizer Inc.
  • Puma Biotechnology, Inc.
  • Shorla Pharma Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Sutro Biopharma, Inc.
  • Takeda Pharmaceutical Company Limited
  • Viatris Inc.
Product Code: MRR-434CCDA05255

The Oncology Drugs Market was valued at USD 175.78 billion in 2023, expected to reach USD 188.41 billion in 2024, and is projected to grow at a CAGR of 7.64%, to USD 294.42 billion by 2030.

The oncology drugs market, defined by its scope of treatment for various cancers, encompasses a wide array of therapeutic modalities, including chemotherapy, immunotherapy, targeted therapy, and hormone therapy. The necessity of oncology drugs is underscored by the rising global cancer incidence, which drives demand for innovative treatments that improve patient survival and quality of life. The application of these drugs spans diverse settings such as hospitals, cancer research centers, and specialized clinics, with end-use extending to pediatric, adult, and geriatric patients. Key growth factors influencing this market include advancements in biotechnology, increased funding for cancer research, and a growing pipeline of novel therapeutics. Moreover, the potential of personalized medicine and the development of biosimilars present lucrative opportunities, with regulatory bodies worldwide emphasizing expedition in drug approvals. To leverage these opportunities, companies should focus on investing in R&D, fostering collaborations with research institutes, and exploring emerging markets with unmet medical needs. However, market growth is challenged by high treatment costs, stringent regulatory frameworks, and potential side effects of therapies, which can hinder patient access and affordability. Furthermore, complex reimbursement scenarios in different regions pose additional delays. Innovation should prioritize precision oncology, which tailors treatments based on genetic profiles, and explore combination therapies that integrate different therapeutic approaches for superior efficacy. Overall, the oncology drugs market is dynamic, characterized by rapid technological evolution and high competition. Companies must remain agile, continuously adapting to scientific advancements and policy changes to maintain their competitive edge. Strategic investments in digital health technologies, such as AI and machine learning, can further enhance drug development processes and patient outcomes, ultimately driving business growth in this robust sector.

KEY MARKET STATISTICS
Base Year [2023] USD 175.78 billion
Estimated Year [2024] USD 188.41 billion
Forecast Year [2030] USD 294.42 billion
CAGR (%) 7.64%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Oncology Drugs Market

The Oncology Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Surging prevalence of cancer across the globe
    • Increase in investments and government funding in development of cancer drugs
    • Growing research & development in personalized medicines
  • Market Restraints
    • High costs associated with the precision medicine therapies
  • Market Opportunities
    • Advancements in genomic sequencing technologies and biotechnology
    • Development of biomarker-driven drug development
  • Market Challenges
    • Stringent regulatory requirements and the complexity of drug development

Porter's Five Forces: A Strategic Tool for Navigating the Oncology Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Oncology Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Oncology Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Oncology Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Oncology Drugs Market

A detailed market share analysis in the Oncology Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Oncology Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Oncology Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Oncology Drugs Market

A strategic analysis of the Oncology Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Oncology Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Agenus Inc., Amgen Inc., Aspen Pharmacare Holdings Limited, Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, BeiGene, Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cipla Limited, Debiopharm International SA, Eli Lilly and Company, EMD Serono, Inc. by Merck KGaA, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Pfizer Inc., Puma Biotechnology, Inc., Shorla Pharma Ltd., Sun Pharmaceutical Industries Ltd., Sutro Biopharma, Inc., Takeda Pharmaceutical Company Limited, and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Oncology Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Indication, market is studied across Bladder Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, Esophagus Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, Prostate Cancer, and Stomach Cancer.
  • Based on Drug Class, market is studied across Chemotherapy, Hormonal Therapy, Immunotherapy, and Targeted Therapy.
  • Based on Route of Administration, market is studied across Intravenous, Oral, and Topical.
  • Based on Distribution, market is studied across Offline Pharmacies and Online Pharmacies. The Offline Pharmacies is further studied across Hospital Pharmacies and Retail Pharmacies.
  • Based on End-use, market is studied across Home Healthcare, Hospitals, and Specialty Cancer Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Surging prevalence of cancer across the globe
      • 5.1.1.2. Increase in investments and government funding in development of cancer drugs
      • 5.1.1.3. Growing research & development in personalized medicines
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with the precision medicine therapies
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in genomic sequencing technologies and biotechnology
      • 5.1.3.2. Development of biomarker-driven drug development
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory requirements and the complexity of drug development
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Class: Growing significance of targeted therapy due to its precision and lower side effects
    • 5.2.2. End-use: Ongoing expansion of specialty cancer clinics accelerating the demand for oncology drugs
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Oncology Drugs Market, by Indication

  • 6.1. Introduction
  • 6.2. Bladder Cancer
  • 6.3. Breast Cancer
  • 6.4. Cervical Cancer
  • 6.5. Colorectal Cancer
  • 6.6. Esophagus Cancer
  • 6.7. Kidney Cancer
  • 6.8. Liver Cancer
  • 6.9. Lung Cancer
  • 6.10. Prostate Cancer
  • 6.11. Stomach Cancer

7. Oncology Drugs Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Chemotherapy
  • 7.3. Hormonal Therapy
  • 7.4. Immunotherapy
  • 7.5. Targeted Therapy

8. Oncology Drugs Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Intravenous
  • 8.3. Oral
  • 8.4. Topical

9. Oncology Drugs Market, by Distribution

  • 9.1. Introduction
  • 9.2. Offline Pharmacies
    • 9.2.1. Hospital Pharmacies
    • 9.2.2. Retail Pharmacies
  • 9.3. Online Pharmacies

10. Oncology Drugs Market, by End-use

  • 10.1. Introduction
  • 10.2. Home Healthcare
  • 10.3. Hospitals
  • 10.4. Specialty Cancer Clinics

11. Americas Oncology Drugs Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Oncology Drugs Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Oncology Drugs Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. FDA Approves XTANDI for High-Risk Prostate Cancer Management
    • 14.3.2. Takeda's FRUZAQLA Receives FDA Approval for Metastatic Colorectal Cance
    • 14.3.3. FDA Approves Takeda's FRUZAQLA, a Novel Treatment for Metastatic Colorectal Cancer
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Agenus Inc.
  • 3. Amgen Inc.
  • 4. Aspen Pharmacare Holdings Limited
  • 5. Astellas Pharma Inc.
  • 6. AstraZeneca PLC
  • 7. Bayer AG
  • 8. BeiGene, Inc.
  • 9. Boehringer Ingelheim GmbH
  • 10. Bristol-Myers Squibb Company
  • 11. Cipla Limited
  • 12. Debiopharm International SA
  • 13. Eli Lilly and Company
  • 14. EMD Serono, Inc. by Merck KGaA
  • 15. F. Hoffmann-La Roche Ltd.
  • 16. GlaxoSmithKline PLC
  • 17. Johnson & Johnson Services, Inc.
  • 18. Pfizer Inc.
  • 19. Puma Biotechnology, Inc.
  • 20. Shorla Pharma Ltd.
  • 21. Sun Pharmaceutical Industries Ltd.
  • 22. Sutro Biopharma, Inc.
  • 23. Takeda Pharmaceutical Company Limited
  • 24. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. ONCOLOGY DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. ONCOLOGY DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ONCOLOGY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ONCOLOGY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. ONCOLOGY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ONCOLOGY DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ONCOLOGY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ONCOLOGY DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BLADDER CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ESOPHAGUS CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY KIDNEY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY STOMACH CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SPECIALTY CANCER CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 60. CANADA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 62. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 64. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 66. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 67. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 70. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 72. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 74. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 84. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 86. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 87. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 88. CHINA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 89. CHINA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 90. CHINA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. CHINA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 92. CHINA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 93. CHINA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 94. INDIA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. INDIA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 96. INDIA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. INDIA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 98. INDIA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 99. INDIA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 100. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 102. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 104. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 105. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 106. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 107. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 108. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 110. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 111. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 112. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 113. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 114. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 116. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 117. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 118. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 120. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 122. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 123. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 124. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 126. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 128. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 129. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 134. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 135. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 136. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 138. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 140. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 141. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 142. THAILAND ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 143. THAILAND ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 144. THAILAND ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. THAILAND ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 146. THAILAND ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 147. THAILAND ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 148. VIETNAM ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 149. VIETNAM ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 150. VIETNAM ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. VIETNAM ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 152. VIETNAM ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 153. VIETNAM ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 161. DENMARK ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 162. DENMARK ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 163. DENMARK ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 164. DENMARK ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 165. DENMARK ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 166. DENMARK ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 167. EGYPT ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 168. EGYPT ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 169. EGYPT ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 170. EGYPT ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 171. EGYPT ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 172. EGYPT ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 173. FINLAND ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 174. FINLAND ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 175. FINLAND ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 176. FINLAND ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 177. FINLAND ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 178. FINLAND ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 179. FRANCE ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 180. FRANCE ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 181. FRANCE ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 182. FRANCE ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 183. FRANCE ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 184. FRANCE ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 185. GERMANY ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 186. GERMANY ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 187. GERMANY ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. GERMANY ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 189. GERMANY ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 190. GERMANY ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 191. ISRAEL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 192. ISRAEL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 193. ISRAEL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 194. ISRAEL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 195. ISRAEL ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 196. ISRAEL ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 197. ITALY ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 198. ITALY ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 199. ITALY ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 200. ITALY ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 201. ITALY ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 202. ITALY ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 204. NETHERLANDS ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 205. NETHERLANDS ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 206. NETHERLANDS ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 207. NETHERLANDS ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 208. NETHERLANDS ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 209. NIGERIA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 210. NIGERIA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 211. NIGERIA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 212. NIGERIA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 213. NIGERIA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 214. NIGERIA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 215. NORWAY ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 216. NORWAY ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 217. NORWAY ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 218. NORWAY ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 219. NORWAY ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 220. NORWAY ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 221. POLAND ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 222. POLAND ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 223. POLAND ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 224. POLAND ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 225. POLAND ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 226. POLAND ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 227. QATAR ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 228. QATAR ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 229. QATAR ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 230. QATAR ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 231. QATAR ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 232. QATAR ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 233. RUSSIA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 234. RUSSIA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 235. RUSSIA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 236. RUSSIA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 237. RUSSIA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 238. RUSSIA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 240. SAUDI ARABIA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 241. SAUDI ARABIA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 242. SAUDI ARABIA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 243. SAUDI ARABIA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 244. SAUDI ARABIA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH AFRICA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 247. SOUTH AFRICA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 248. SOUTH AFRICA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 249. SOUTH AFRICA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 250. SOUTH AFRICA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 251. SPAIN ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 252. SPAIN ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 253. SPAIN ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 254. SPAIN ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 255. SPAIN ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 256. SPAIN ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 257. SWEDEN ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 258. SWEDEN ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 259. SWEDEN ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 260. SWEDEN ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 261. SWEDEN ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 262. SWEDEN ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 264. SWITZERLAND ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 265. SWITZERLAND ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 266. SWITZERLAND ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 267. SWITZERLAND ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 268. SWITZERLAND ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 269. TURKEY ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 270. TURKEY ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 271. TURKEY ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 272. TURKEY ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 273. TURKEY ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 274. TURKEY ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED ARAB EMIRATES ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED ARAB EMIRATES ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED ARAB EMIRATES ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 280. UNITED ARAB EMIRATES ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 282. UNITED KINGDOM ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 283. UNITED KINGDOM ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 284. UNITED KINGDOM ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 285. UNITED KINGDOM ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 286. UNITED KINGDOM ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 287. ONCOLOGY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 288. ONCOLOGY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023